These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
549 related articles for article (PubMed ID: 26787002)
1. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis. Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J Liver Int; 2016 Jun; 36(6):817-26. PubMed ID: 26787002 [TBL] [Abstract][Full Text] [Related]
2. Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis. Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J J Gastroenterol Hepatol; 2017 Mar; 32(3):687-694. PubMed ID: 27577675 [TBL] [Abstract][Full Text] [Related]
3. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan. Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762 [TBL] [Abstract][Full Text] [Related]
4. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234 [TBL] [Abstract][Full Text] [Related]
5. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617 [TBL] [Abstract][Full Text] [Related]
6. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients. Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511 [TBL] [Abstract][Full Text] [Related]
8. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. van der Meer AJ; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Heathcote EJ; Manns MP; Kuske L; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL JAMA; 2012 Dec; 308(24):2584-93. PubMed ID: 23268517 [TBL] [Abstract][Full Text] [Related]
9. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. Hung CH; Lee CM; Wang JH; Hu TH; Chen CH; Lin CY; Lu SN Int J Cancer; 2011 May; 128(10):2344-52. PubMed ID: 20669224 [TBL] [Abstract][Full Text] [Related]
10. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study. Nagaoki Y; Aikata H; Nakano N; Shinohara F; Nakamura Y; Hatooka M; Morio K; Kan H; Fujino H; Kobayashi T; Fukuhara T; Masaki K; Ono A; Nakahara T; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Imamura M; Takahashi S; Kawakami Y; Ochi H; Chayama K; J Gastroenterol Hepatol; 2016 May; 31(5):1009-15. PubMed ID: 26584407 [TBL] [Abstract][Full Text] [Related]
11. Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor. Kanogawa N; Ogasawara S; Chiba T; Saito T; Motoyama T; Suzuki E; Ooka Y; Tawada A; Kanda T; Mikami S; Azemoto R; Kaiho T; Shinozaki M; Ohtsuka M; Miyazaki M; Yokosuka O J Gastroenterol Hepatol; 2015 Jul; 30(7):1197-204. PubMed ID: 25682720 [TBL] [Abstract][Full Text] [Related]
12. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study. Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765 [TBL] [Abstract][Full Text] [Related]
13. Estimating the impact of early hepatitis C virus clearance on hepatocellular carcinoma risk. Darvishian M; Janjua NZ; Chong M; Cook D; Samji H; Butt ZA; Yu A; Alvarez M; Yoshida E; Ramji A; Wong J; Woods R; Tyndall M; Krajden M J Viral Hepat; 2018 Dec; 25(12):1481-1492. PubMed ID: 30047609 [TBL] [Abstract][Full Text] [Related]
14. Long-term cohort study of chronic hepatitis C according to interferon efficacy. Maruoka D; Imazeki F; Arai M; Kanda T; Fujiwara K; Yokosuka O J Gastroenterol Hepatol; 2012 Feb; 27(2):291-9. PubMed ID: 21793911 [TBL] [Abstract][Full Text] [Related]
15. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance. Huang CF; Yeh ML; Huang CI; Lin YJ; Tsai PC; Lin ZY; Chan SY; Chen SC; Yang HI; Huang JF; Lu SN; Dai CY; Jen CL; Yuan Y; L'Italien G; Wang LY; Lee MH; Yu ML; Chuang WL; Chen CJ Oncotarget; 2017 Jul; 8(27):43925-43933. PubMed ID: 28159934 [TBL] [Abstract][Full Text] [Related]
16. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy. Nagaoki Y; Imamura M; Nishida Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Fujino H; Nakahara T; Kawaoka T; Tsuge M; Hiramatsu A; Kawakami Y; Miki D; Hiyama Y; Ochi H; Chayama K; Aikata H J Med Virol; 2019 Apr; 91(4):650-658. PubMed ID: 30381831 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B. Toyoda H; Kumada T; Tada T; Shimada N; Takaguchi K; Senoh T; Tsuji K; Tachi Y; Hiraoka A; Ishikawa T; Shima T; Okanoue T J Hepatol; 2017 Mar; 66(3):521-527. PubMed ID: 27890790 [TBL] [Abstract][Full Text] [Related]
18. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. Toyoda H; Kumada T; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Ito T J Gastroenterol Hepatol; 2015 Jul; 30(7):1183-9. PubMed ID: 25678094 [TBL] [Abstract][Full Text] [Related]
19. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. Kobayashi M; Suzuki F; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H J Med Virol; 2017 Mar; 89(3):476-483. PubMed ID: 27531586 [TBL] [Abstract][Full Text] [Related]
20. Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis. McDonald SA; Pollock KG; Barclay ST; Goldberg DJ; Bathgate A; Bramley P; Dillon JF; Fraser A; Innes HA; Kennedy N; Morris J; Went A; Hayes PC; Hutchinson SJ J Viral Hepat; 2020 Mar; 27(3):270-280. PubMed ID: 31696575 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]